Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1α expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy

Neuro-Oncology

Volumn 7, Issue 3, 2005, Pages 225-235

  Newcomb, Elizabeth W ^a   Ali, M Aktar ^a   Schnee, Tona ^a   Lan, Li ^a   Lukyanov, Yevgeniy ^a   Fowkes, Mary ^a   Miller, Douglas C ^a   Zagzag, David ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Flavopiridol; Glioma; HIF 1 ; Hypoxia; Proteasome inhibitor; VEGF

Indexed keywords

FLAVOPIRIDOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MG 262; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN REGULATION; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR VASCULARIZATION;

ANIMALS; ANOXIA; BLOTTING, WESTERN; BORONIC ACIDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; FLAVONOIDS; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 2; MICE; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; POLYMERASE CHAIN REACTION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23144447809     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1152851704000997     Document Type: Article

References (54)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., and Elliott, P.J. (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
2. Alonso, M., Tamasdan, C., Miller, D.C., and Newcomb, E.W. (2003) Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol. Cancer Ther. 2, 139-150.
3. Blagosklonny, M.V. (2004) Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 3, 1537-1542.
4. Brat, D.J., Castellano-Sanchez, A.A., Hunter, S.B., Pecot, M., Cohen, C., Hammond, E.H., Devi, S.N., Kaur, B., and Van Meir, E.G. (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64, 920-927.
5. Brown, J.M., and Giaccia, A.J. (1998) The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
6. Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D., Keshert, E., and Keshet, E. (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
7. Chan, D.A., Sutphin, P.D., Denko, N.C., and Giaccia, A.J. (2002) Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J. Biol. Chem. 277, 40112-40117.
8. Chao, S.H., and Price, D.H. (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793-31799.
9. Dai, Y., Rahmani, M., and Grant, S. (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene 22, 7108-7122.
10. Damert, A., Machein, M., Breier, G., Fujita, M.Q., Hanahan, D., Risau, W., and Plate, K.H. (1997) Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 57, 3860-3864.
11. de Azevedo, W.F., Jr., Canduri, F., and da Silveira, N.J. (2002) Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293, 566-571.
12. Deryugina, E.I., Soroceanu, L., and Strongin, A.Y. (2002) Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 62, 580-588.
13. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K.H., and Augustin, H.G. (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393.
14. Ellerbroek, S.M., Wu, Y.I., Overall, C.M., and Stack, M.S. (2001) Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem. 276, 24833-24842.
15. Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., and Semenza, G.L. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604-4613.
16. Gojo, I., Zhang, B., and Fenton, R.G. (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 8, 3527-3538.
17. Guillemin, K., and Krasnow, M.A. (1997) The hypoxic response: Huffing and HIFing. Cell 89, 9-12.
18. Hotary, K., Allen, E., Punturieri, A., Yana, I., and Weiss, S.J. (2000) Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 149, 1309-1323.
19. Huang, L.E., Arany, Z., Livingston, D.M., and Bunn, H.F. (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J. Biol. Chem. 271, 32253-32259.
20. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95, 7987-7992.
21. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A.C., and Van Meir, E.G. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9, 469-479.
22. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162.
23. 2 tension. Am. J. Physiol. 271, C1172-C1180.
24. Jiang, B.H., Agani, F., Passaniti, A., and Semenza, G.L. (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328-5335.
25. Kallio, P.J., Wilson, W.J., O'Brien, S., Makino, Y., and Poellinger, L. (1999) Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274, 6519-6525.
26. Kerr, J.S., Wexler, R.S., Mousa, S.A., Robinson, C.S., Wexler, E.J., Mohamed, S., Voss, M. E., Devenny, J.J., Czerniak, P.M., Gudzelak, A., Jr., and Slee, A.M. (1999) Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anti-cancer Res. 19, 959-968.
27. Kitagawa, H., Tani, E., Ikemoto, H., Ozaki, I., Nakano, A., and Omura, S. (1999) Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett. 443, 181-186.
28. Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K., and Quaranta, V. (2000) Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148, 615-624.
29. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., and Semenza, G.L. (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63, 1138-1143.
30. Li, Y., Bhuiyan, M., Alhasan, S., Senderowicz, A.M., and Sarkar, F.H. (2000) Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin. Cancer Res. 6, 223-229.
31. Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., and Ratcliffe, P.J. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
32. Melillo, G., Sausville, E.A., Cloud, K., Lahusen, T., Varesio, L., and Senderowicz, A.M. (1999) Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 59, 5433-5437.
33. Munaut, C., Noel, A., Hougrand, O., Foidart, J.M., Boniver, J., and Deprez, M. (2003) Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int. J. Cancer 106, 848-855.
34. Nawrocki, S.T., Sweeney-Gotsch, B., Takamori, R., and McConkey, D.J. (2004) The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 3, 59-70.
35. Newcomb, E.W. (2004) Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity. Anti-cancer Drugs 15, 411-419.
36. Newcomb, E.W., Tamasdan, C., Entzminger, Y., Arena, E., Schnee, T., Kim, M., Crisan, D., Lukyanov, Y., Miller, D.C., and Zagzag, D. (2004) Flavopiridol inhibits the growth of GL261 gliomas in vivo: Implications for malignant glioma therapy. Cell Cycle 3, 230-234.
37. Orlowski, R.Z., and Baldwin, A.S., Jr. (2002) NF-κB as a therapeutic target in cancer. Trends Mol. Med. 8, 385-389.
38. Rapella, A., Negrioli, A., Melillo, G., Pastorino, S., Varesio, L., and Bosco, M.C. (2002) Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int. J. Cancer 99, 658-664.
39. Rapisarda, A., Uranchimeg, B., Scudiero, D.A., Selby, M., Sausville, E.A., Shoemaker, R.H., and Melillo, G. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324.
40. Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., and Bedi, A. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44.
41. Salceda, S., and Caro, J. (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642-22647.
42. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578.
43. Senderowicz, A.M. (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22, 6609-6620.
44. Shannon, A.M., Bouchier-Hayes, D.J., Condron, C.M., and Toomey, D. (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29, 297-307.
45. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
46. Takada, Y., and Aggarwal, B.B. (2004) Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J. Biol. Chem. 279, 4750-4759.
47. Tergaonkar, V., Bottero, V., Ikawa, M., Li, Q., and Verma, I.M. (2003) IκB kinase-independent IκBα degradation pathway: Functional NF-κB activity and implications for cancer therapy. Mol. Cell Biol. 23, 8070-8083.
48. Unruh, A., Ressel, A., Mohamed, H.G., Johnson, R.S., Nadrowitz, R., Richter, E., Katschinski, D.M., and Wenger, R.H. (2003) The hypoxia-inducible factor-1 α is a negative factor for tumor therapy. Oncogene 22, 3213-3220.
49. Voorhees, P.M., Dees, E.C., O'Neil, B., and Orlowski, R.Z. (2003) The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316-6325.
50. 2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
51. Zagzag, D., Zhong, H., Scalzitti, J.M., Laughner, E., Simons, J.W., and Semenza, G.L. (2000) Expression of hypoxia-inducible factor 1α in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618.
52. Zagzag, D., Shiff, B., Jallo, G.I., Greco, M.A., Blanco, C., Cohen, H., Hukin, J., Allen, J.C., and Friedlander, D.R. (2002) Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 62, 2660-2668.
53. Zagzag, D., Nomura, M., Friedlander, D.R., Blanco, C.Y., Gagner, J.P., Nomura, N., and Newcomb, E.W. (2003) Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1α) in glioma cell invasion. J. Cell Physiol. 196, 394-402.
54. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A.R., Ryan, H.E., Johnson, R.S., Jefferson, A.B., Stokoe, D., and Giaccia, A.J. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396.